moxifloxacin has been researched along with prothionamide in 6 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (prothionamide) | Trials (prothionamide) | Recent Studies (post-2010) (prothionamide) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 219 | 28 | 46 |
| Protein | Taxonomy | moxifloxacin (IC50) | prothionamide (IC50) |
|---|---|---|---|
| Polyphenol oxidase 2 | Agaricus bisporus | 4.5 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 6 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chiang, CY; Madan, J; Meredith, SK; Nunn, AJ; Phillips, PP; Rusen, ID; Squire, SB; Torrea, G; Van Deun, A | 1 |
| Chung, JY; Jang, IJ; Jang, K; Lee, JH; Moon, SJ; Oh, J; Park, JS; Park, SI; Song, J; Yoon, J; Yu, KS | 1 |
| Ghim, JR; Kim, DH; Kim, JH; Lee, HK; Lee, SH; Lee, YM; Seo, KA; Shin, C; Shin, JG | 1 |
| Akkerman, OW; Bathoorn, E; de Lange, WCM; Lokate, M; Louka, C; Pournaras, S; Ravensbergen, SJ; Stienstra, Y; van der Werf, TS | 1 |
| Cao, P; Doan, TN; Emeto, TI; McBryde, ES; McCaw, JM | 1 |
2 trial(s) available for moxifloxacin and prothionamide
| Article | Year |
|---|---|
Evaluation of a standardized treatment regimen of anti-tuberculosis drugs for patients with multi-drug-resistant tuberculosis (STREAM): study protocol for a randomized controlled trial.
Topics: Antitubercular Agents; Bangladesh; Clinical Protocols; Clofazimine; Drug Administration Schedule; Drug Therapy, Combination; Ethambutol; Fluoroquinolones; Humans; Isoniazid; Kanamycin; Moxifloxacin; Prothionamide; Pyrazinamide; Research Design; Time Factors; Treatment Outcome; Tuberculosis, Multidrug-Resistant; Tuberculosis, Pulmonary | 2014 |
Pharmacokinetics of Second-Line Antituberculosis Drugs after Multiple Administrations in Healthy Volunteers.
Topics: Adult; Aminosalicylic Acid; Antitubercular Agents; Area Under Curve; Cycloserine; Drug Monitoring; Fluoroquinolones; Healthy Volunteers; Humans; Kanamycin; Levofloxacin; Male; Moxifloxacin; Prothionamide; Pyrazinamide; Streptomycin; Young Adult | 2015 |
4 other study(ies) available for moxifloxacin and prothionamide
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Low Serum Concentrations of Moxifloxacin, Prothionamide, and Cycloserine on Sputum Conversion in Multi-Drug Resistant TB.
Topics: Adult; Aged; Antitubercular Agents; Chromatography, High Pressure Liquid; Cycloserine; Fluoroquinolones; Humans; Medication Adherence; Middle Aged; Moxifloxacin; Prothionamide; Retrospective Studies; Sputum; Tandem Mass Spectrometry; Tuberculosis, Multidrug-Resistant; Young Adult | 2015 |
Case Report: Carbapenemase-Producing Enterobacteriaceae in an Asylum Seeker with Multidrug-Resistant Tuberculosis.
Topics: Adult; Amikacin; Carbapenem-Resistant Enterobacteriaceae; Clofazimine; Drug Monitoring; Humans; Linezolid; Male; Moxifloxacin; Netherlands; Prevalence; Prothionamide; Refugees; Trimethoprim, Sulfamethoxazole Drug Combination; Tuberculosis, Multidrug-Resistant | 2018 |
Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.
Topics: Antitubercular Agents; Clofazimine; Colony Count, Microbial; Computer Simulation; Diarylquinolines; Dose-Response Relationship, Drug; Drug Dosage Calculations; Drug Resistance, Bacterial; Drug Therapy, Combination; Ethambutol; Host-Pathogen Interactions; Humans; Immunity, Innate; Isoniazid; Kanamycin; Macrophages; Microbial Sensitivity Tests; Models, Statistical; Moxifloxacin; Mycobacterium tuberculosis; Ofloxacin; Prothionamide; Pyrazinamide; Time Factors; Tuberculosis, Multidrug-Resistant | 2018 |